1521 — Frontage Holdings Share Price
Last trade - 00:00- HK$2.24bn
- HK$3.10bn
- $254.91m
- 65
- 44
- 60
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.59 | ||
| PEG Ratio (f) | 0.24 | ||
| EPS Growth (f) | 347.59% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.91 | ||
| Price to Tang. Book | 2.62 | ||
| Price to Free Cashflow | 7.48 | ||
| Price to Sales | 1.19 | ||
| EV to EBITDA | 8.36 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.73% | ||
| Return on Equity | 0.23% | ||
| Operating Margin | 4.73% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 125.81 | 184.44 | 250.36 | 259.86 | 254.91 | 279.54 | 310.76 | 20.48% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -23.47 | +6.87 | +41.91 | -52.27 | -94.07 | +1328.86 | +200 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Frontage Holdings Corporation is a holding company. It provides laboratory and related services to pharmaceutical and agrochemical companies, as well as bioequivalence clinical and chemical services. The Company has two main divisions: Global Laboratory Services and Global Drug Discovery & Development Services. The Global Laboratory Services division offers laboratory testing support for clients involved in drug development. The Global Drug Discovery & Development Services division includes Drug Development Unit, the Drug Discovery Unit, and the Pharmaceutical Product Development Unit. Its Global Laboratory Services encompass regulated and non-regulated bioanalysis (both small and large molecules), biomarkers, genomics, manufacturing and controls analytical testing, and central laboratory services. The Drug Development Unit includes drug metabolism and pharmacokinetics, Safety and Toxicology. The Company's segments include North America and Europe and PRC.
Directors
- Li Song CHM (63)
- Wang Yifeng CFO (49)
- Zhongping Lin EVP (55)
- Abdul Mutlib EVP (58)
- Tianyi Zhang SVP (50)
- Hugh Davis OTH (60)
- Karen Chang SEC (55)
- Jun Gao NED (46)
- Yifan Li NID (54)
- Erhfei Liu NID (62)
- Jingsong Wang NID (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 16th, 2018
- Public Since
- May 30th, 2019
- No. of Employees
- 1,560
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,999,545,910
- Address
- 700 Pennsylvania Drive, Exton, 19341-1129
- Web
- https://www.frontagelab.com/
- Phone
- +1 6102320100
- Auditors
- BDO LTD
Latest News for 1521
Upcoming Events for 1521
Frontage Holdings Corp Annual Shareholders Meeting
Frontage Holdings Corp Annual Shareholders Meeting
Half Year 2025 Frontage Holdings Corp Earnings Release
Similar to 1521
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 20:42 UTC, shares in Frontage Holdings are trading at HK$1.18. This share price information is delayed by 15 minutes.
Shares in Frontage Holdings last closed at HK$1.18 and the price had moved by -9.23% over the past 365 days. In terms of relative price strength the Frontage Holdings share price has underperformed the FTSE Developed Asia Pacific Index by -8.19% over the past year.
The overall consensus recommendation for Frontage Holdings is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreFrontage Holdings does not currently pay a dividend.
Frontage Holdings does not currently pay a dividend.
Frontage Holdings does not currently pay a dividend.
To buy shares in Frontage Holdings you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$1.18, shares in Frontage Holdings had a market capitalisation of HK$2.24bn.
Here are the trading details for Frontage Holdings:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1521
Based on an overall assessment of its quality, value and momentum Frontage Holdings is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Frontage Holdings is HK$1.14. That is 3.02% below the last closing price of HK$1.18.
Analysts covering Frontage Holdings currently have a consensus Earnings Per Share (EPS) forecast of $0.01 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Frontage Holdings. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +68.97%.
As of the last closing price of HK$1.18, shares in Frontage Holdings were trading +10.75% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Frontage Holdings PE ratio based on its reported earnings over the past 12 months is 18.59. The shares last closed at HK$1.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Frontage Holdings' management team is headed by:
- Li Song - CHM
- Wang Yifeng - CFO
- Zhongping Lin - EVP
- Abdul Mutlib - EVP
- Tianyi Zhang - SVP
- Hugh Davis - OTH
- Karen Chang - SEC
- Jun Gao - NED
- Yifan Li - NID
- Erhfei Liu - NID
- Jingsong Wang - NID